Table Of Content

Author Index, Volume 38 (1998) Achari R, 545 Buell D, 583 Dodo H, 496 Graves RW, 554 Adedoyin A, 82 BUFUL Study Group, 630 Donders SH, 630 Grebow P, 971 Agerso H, 1051 Bugge C, 447 Doose DR, 90 Grebow PE, 276 Agrawal MA, 533 Buier R, 357 Dorr A, 1057 Greenberg HE, 283 Ahlberg AW, 792 Burckart GJ, 981 Druce HM, 382 Greenblatt DJ, 14, 106, 112, Aigner KR, 936 Burdick J, 561 Duan SX, 106 572, 603 Ajami A, 309 Burggraaf J, 45 Dube LM, 642 Greene DS, 433, 702 Aldrich TK, 364 Burke J, 256 Griffy K, 1021, 1057, 1122 Allain H, 256 Eastmond R, 819 Groes L, 1051 Allard S, 1042 Cantore M, 936 Ebert U, 720 Groghan IT, 502 Altorf B, 1129 Cavanaugh J, 545 Ehrenberg BL, 14 Guadagni S, 936 Amsden GW, 424 Cevallos W, 744 Eldon R, 971 Guilbert E, 1042 Anandasabapathy S, 101, Chan DCF, 912 Elihu N, 101 Guinta D, 60 295 Chando TJ, 702 Eller MG, 517 Gulanski B, 236 Anderson GD, 815 Chandrasekaran A, 744 Emmert SE, 525 Gumbhir-Shah K, 1096 Andreadou I, 825 Chan K, 744 Engelhardt N, 603 Gupta SK, 60, 951 Afionuevo J, 618 Chan P, 1151 Epinette WW, 368 Gurell D, 887 Apseloff G, 830 Chapelsky MC, 34, 129 Ermer J, 744 Gwilt PR, 945 Arancibia A, 533 Chapman S, 736 Etheredge R, 34 Arnett DK, 202 Chaudhuri PK, 936 Etheredge RC, 54 Haak R, 951 Arumugham T, 798 Cheng A, 477 Ette EI, 221, 417 Halstenson C, 798 Ashford JW, 236 Chen Y, 971 Eustace J, 561 Hammett JL, 1116 Awni WM, 642 Chen Y-J, 1151 Everett DW, 702 Harder S, 904 Axelson JE, 496 Chiang ST, 467 Harmatz JS, 14, 106, 112, Chien SC, 90 Fairless AJ, 54 603 Babul N, 74 Ching MI, 151 Fan C, 172 Harris RZ, 1137 Baker AB, 160 Choi M, 561 Farrar HC, 1089 Harsanyi Z, 74 Bakos L, 554 Cho MJ, 807 Farrar HC III, 1010 Hartman L, 971 Bank AK, 202 Chow C-C, 912 Fasules JW, 402 Hassell AE, 593 Barakat H, 1107 Chow MSS, 28, 172, 792 Ferraro-Borgida MJ, 792 Heller AH, 715 Barbhaiya RH, 433, 702 Chung M, 1072 Finkelstein SM, 202 Heller GV, 792 Barditch-Crovo P, 357 Cleary EW, 685 Fiorentini G, 936 Heulitt MJ, 402 Baroldi P, 545 Clendeninn N, 736 Flanigan M, 959 Higgs C, 736 Baruch A, 593 Cleophas TJ, 630 Floc’h R, 807 Hilbert J, 1072 Bauer KS, 337 Clerice M, 936 Fogelman SM, 106 Hillerup S, 447 Bazunga M, 28, 172 Cockram CS, 912 Folan MM, 337 Himeno H, 442 Bekersky I, 583 Cohen A, 545 Forbes WP, 144 Hiroto S, 442 Benet LZ, 1137 Cohen AF, 45, 966, 1129 Ford NF, 246, 347 Hoerr R, 373 Berkovitch M, 926 Cohn JN, 202 Forrest A, 151, 649, 1063 Holz-Slomczyk M, 904 Bernink PJ, 630 Colborn D, 1042 Foss JF, 931, 1017 Horton M, 798 Bernstein KJ, 951 Colburn W, 1021, 1122 Foulds G, 830 Hosmane B, 545 Bhatta S, 765 Colburn WA, 199 Fransua M, 393 Huang T-Y, 1151 Biber A, 373 Colucci WS, 525 Freedom R, 496 Huang W-P, 1151 Bieber F, 236 Colussi DM, 727 French S, 694 Huffman CS, 685 Bleske BE, 708 Cowart DT, 429 Frishman WH, 2, 101, 295, Hulse J, 1021, 1057, 1122 Blume H, 904 Cramer MB, 798 393, 477, 765, 887, 1077 Hurt RD, 22, 502, 510 Blumer JL, 122 Cressman MD, 670 Frye RF, 82 Hwang S, 60 Blum R, 368 Croghan IT, 22, 510 Furey SA, 382 Boeijinga JK, 966 Crout RJ, 554 Furtek CI, 525 Igarashi T, 1025 Boike S, 649 Cummings DM, 1107 Ilson B, 129, 649 Boike SC, 34, 54, 129, 437 Galant S, 382 Ilson BE, 34, 437 Bolton S, 408 Daily JP, 106 Gandon J-M, 256 Imbimbo BP, 610 Borum J, 593 Dale LC, 502, 510 Gharaibeh MN, 492 Ito MK, 331 Borum P, 357 Danjou P, 256 Gibaldi M, 898 Ito S, 496 Boswell GW, 583 DeGraw S, 1096 Giesbrecht E, 496 Izzo JL Jr, 151 Bramer SL, 144, 429 Delvaux M, 694 Gillen LP, 492 Branch RA, 82, 670 de Planque BA, 630 Gimenez LF, 561 Jackson DL, 554 Brandon ML, 382 Deraco M, 936 Glasser SP, 202, 659 Jackson EK, 670 Branebjerg PE, 447 Derendorf H, 373 Gleiter CH, 680, 904 James LP, 1089 Brayman KL, 268 de Visser Sj, 1129 Goddard JE, 14 Jara H, 918 Briggs WA, 561 Dicpinigaitis PV, 364 Goldberg D, 357 Jiang N-S, 502, 510 Browne DG, 309 Dilzer SC, 685 Goldman M, 593 Jochemsen R, 315 Browne TR, 213, 309 Dimmitt DC, 798 Gow R, 496 Jorkasky DK, 34, 54, 129, Brueckner RP, 227 Dixon R, 694 Granda BW, 106 413, 437, 649 Buchanan RA, 166 Dobkin JB, 364 Grassi JM, 106 Jovanovic L, 636 Jung D, 1021, 1057, 1122 LeBel M, 1042 Meinders AJ, 1129 Pak CYC, 1035 Jusko WJ, 1096, 1116 Lechin AE, 918 Meineke I, 680 Palumbo G, 936 Lechin F, 918 Merz M, 1144 Papadimitriou L, 825 Kaiser L, 715 Lechin ME, 918 Mick R, 268 Paquet F, 1042 Kalayjian RC, 357 Leclerc V, 694 Miller VM, 22 Parisot CY, 727 Kaminskis A, 227 Le Coz F, 256 Minamisawa K, 442 Park J-S, 433 Kanamaru M, 40 Lederman M, 357 Min DI, 959 Pastuszak A, 926 Kaplan GB, 14 Lee J-I, 981 Miura T, 654 Patat A, 256 Kashuba ADM, 424 Lee P, 593 Mizutani M, 654 Paulos C, 533 Kates RE, 1057 Lefévre GY, 727 Monaghan J, 736 Paulus H, 904 Kato K, 1025 Lehmann DF, 463, 783 Montgomery PA, 184 Perhach JL, 184 Kato T, 1025 Lester RS, 926 Moore LW, 807 Pesco-Koplowitz L, 593 Kazierad DJ, 618, 649 Lettieri J, 236, 715 Moore PA, 554 Peters R, 166 Kearns GL, 122, 402, 424, Lettis S, 819 Moran HB, 807 Pettigrew LC, 236 994, 1010, 1089 Letzig L, 994 Morgan DJ, 202 Phillips K, 1072 Keefe DL, 1, 569 Letzig LG, 1010 Morse PD, 463 Pieters MSM, 1129 Kellerman DJ, 1096 Levitsky J, 887 Moss J, 931, 1017 Poethko-Miiller C, 904 Kemp J, 694 Levy R, 807 Moulin D, 74 Poindexter J, 1035 Kertland H, 28 Lewis DA, 22 Moyle GJ, 736 Pollack GM, 807 Keung ACF, 517 Lietman P, 357 Moyna NM, 792 Post JB IV, 2 Kihara M, 442 Lilley SH, 1107 Mroczkowski PJ, 1137 Pouletty P, 807 Kinameri K, 1025 Lin E;:227 Mullican W, 715 Pouriezis T, 825 King SP, 276 Linnen P, 545 Mure P, 382 Pozone T, 936 Kirch W, 720 Liu BA, 1003 Prenner BM, 382 Kisicki J, 429 Liu Y-C, 1151 Nafziger AN, 424 Prince W, 736 Klein J, 926 Li X-Y, 945 Nagai H, 1025 Provencher L, 74 Klotz U, 904 Lockhart EA, 382 Nagai N, 1025 Kluger J, 172 Loi C-M, 178, 815 Nagamochi I, 442 Rada I, 918 Knowles SR, 1003 Lo M-W, 525 Nakamura K, 68 Radick LE, 945 Knowlton PW, 178 Liicker PW, 533 Nakano S, 68 Ramey KL, 413 Kochak GM, 166 Ludden TM, 221, 417 Nakashima M, 40, 540 Ramzan I, 160 Koch P, 1096 Lu H, 525 Nakatsuka K, 68 Randinitis EJ, 178 Ko GTC, 912 Lu W, 625 Nanhekhan LV, 1129 Raschke R, 1057 Koneru B, 429 Luzier AB, 618 Narang PK, 1042 Rauf K, 364 Korecka M, 268 Lyness WH, 184 Narang-Sachdeo S, 184 Rautureau J, 694 Koren G, 496, 926 Naruse M, 442 Raymond RH, 347 Koshiba Y, 1025 Mahmood I, 324 Nattestad A, 447 Reed MD, 122 Kost CK Jr, 670 Maish WA, 1010 Nawarskas JJ, 618 Regaglia F, 160 Kostopanagiotou G, 825 Mak TWL, 912 Nayak RK, 90 Ritschel WA, 533 Kotegawa T, 68 Mantha S, 433 Nelson MR, 736 Ritter MA, 525 Kottis G, 825 Mant T, 610 Neuman E, 315 Ritzau M, 447 Koup JR, 178, 815 Marino MR, 246, 347 Newman N, 463 Roizen MF, 931, 1017 Kovacs SJ, 413 Marino MT, 227 Nicklas JM, 708 Rosenberg A, 184 Kraft W, 283 Markesbery WR, 236 Nielsen H, 447 Rosenberg HC, 496 Kramer WG, 708 Markland C, 971 Niemeyer MG, 630 Rowe WB, 357 Kroboth PD, 337 Marotti T, 1089 Nix DE, 1063 Rucinska E, 525 Kroon JM, 1129 Marrero I, 1155 Noe D, 357 Rud KS, 22 Kruse T, 1051 Marshall JD, 994 Noorduin H, 951 Rudolph R, 467 Kuhlmann J, 904 Martin DE, 34, 129, 413, Noorisa M, 429 Ruml LA, 1035 Kurita Y, 1025 437, 649 Nowak I, 268 Ruzicka BB, 236 Ku Y-M, 959 Maruyama I, 540 Nulman I, 926 Mas J, 236 Sachdeo RC, 184 Laberge F, 74 Massarelle J, 28 O’Connor M, 931, 1017 Sathyan G, 951 LaBoy-Goral L, 830 Masson E, 1042 O’Dea RF, 642 Sawyer CA, 160 Lachaud-Pettiti V, 315 Masuhara K, 1025 Oertel R, 720 Scatina J, 744 Lam CWK, 912 Mathew S, 561 Offord KP, 22, 502, 510 Scavone JM, 603 Langenbacher K, 246 Matsukubo S, 68 Ogata H, 1025 Schade DS, 636 Langenbacher KM, 347 Matzke GR, 82 Ohno T, 1025 Scharpf F, 138 Lasagna L, 570, 575 Mauro K, 82 Olson NZ, 1155 Scheel PJ Jr, 561 Lasseter KC, 227, 347, 685 Mayersohn M, 467 Olson SC, 753 Schentag JJ, 1063 Laufen H, 138 Mazzu A, 715 Orazem J, 236 Schmider J, 112 Laughton W, 971 McCormick GC, 276 Orozco B, 918 Schmitt FA, 236 Laughton WB, 276 McCubbin MM, 1010 Osborne B, 492 Schneider J, 636 Laveille C, 315 McGill CC, 792 Osman M, 744 Schneider LG, 554 Lawrence V, 1072 McVeigh GE, 202 Otvos J, 1107 Schoemaker RC, 45, 1129 Lawson GM, 502, 510 Medicis J, 783 Schook CE, 966 Lazarus SC, 577 Mehlisch DR, 455 Padgett CS, 166 Schou S, 447 Leaf CD, 945 Meikle AW, 54 Page JG, 166 Schroeder DR, 502, 510 Schroeder TJ, 807 Sugiura Y, 654 Uchida E, 1129 Wesnes KA, 720 Schuster BG, 227 Sung BH, 151 Uchida N, 1129 Wetzelsberger KM, 533 Schwartzel E, 368 Sun H, 221, 417 Uderman HD, 246 Whalen JJ, 945 Schwartz JI, 492 Sunshine A, 1155 Ueda S, 442 Wheat LJ, 593 Sedman AJ, 178 Suri A, 144 Uematsu T, 540 White CM, 172, 792 Seiberling M, 1144 Sweeney JA, 337 Ueno K, 654 Willavize S, 830 Sellers M, 694 Szabo GK, 309 Umemura K, 40, 540 Williams RR, 90 Shader RI, 14, 106, 112, Uretsky BF, 525 Wilson DE, 54 603 Takahashi H, 1025 Wilson MF, 151, 618 Shah AK, 798 Takano Y, 654 Woestenborghs R, 593 Shah J, 60 Takasaki I, 442 Vachharajani NN, 433, 702 Wong R, 1021, 1122 Vadlamudi S, 1107 Sharma A, 1116 Takatsu F, 654 Wong SL, 642 Shaw LM, 268 Tanaka K, 654 Vahdat S, 765 Wong YN, 276, 971 Shear N, 926 Tanaka Y, 1025 Vallée F, 1042 Woods JH, 773 van den Anker JN, 122 Shear NH, 1003 Tarnowski TL, 1057 Wright CE, 337 van den Ende R, 966 Shibakawa M, 654 Taylor BJ, 402, 1089 van der Dijs B, 918 Wuermser L-A, 1035 Shindo K, 442 Tenero D, 129 van der Heijden M, 630 Wu J, 593 Shionoiri H, 442 Tenero DM, 34 van der Meulen J, 630 Shumaker RC, 184 Terpstra IJ, 45 Shyu WC, 433, 702 Theodoraki K, 825 van der Wall EE, 630 Xia Q, 625 Siepmann M, 720 Thoden WR, 382 van Gerven JMA, 1129 Xie T, 382 van Meegen E, 966 Simcoe D, 971 Thomann P, 1144 Sinha S, 1077 Thompson PD, 792 Van Peer A, 951 Vashi V, 1072 Yashar PR, 393 SSiisskeinnw iSn,e 36S8F , 744 TTihkohmtsmeann MASJ,, 213065 1 Vassos AB, 178 Yasuda G, 442 Skoglund LA, 447 Tirado S, 1155 Venkatakrishnan K, 112 Yasuda K, 1129 Verjee Z, 496 Yasuhara H, 1129 Skowron G, 357 Tofovic SP, 670 Slugg PH, 1116 Toh J, 525 Vincent J, 830 Yatsuka YI, 68 von Moltke LL, 106, 112 Yeates R, 138 Smith CD, 236 Tonn GR, 496 Yeung VTF, 912 Smith DA, 685 Tran C, 1003 Yokoyama A, 1025 Smithers JA, 753 Tran HT, 28 Wada Y, 1025 Youle M, 736 Smyrniotis V, 825 Trépanier EF, 424 Waldman SA, 283, 492 Young MA, 819 Someya K, 1025 Trocherie S, 256 Walker SA, 90 Yuan C-S, 931, 1017 Sourgens H, 373 Troetel WM, 610 Wang L, 971 Spivey JM, 1107 Troy S, 256 Watkins S, 685 Stanislaus F, 904 Troy SM, 467 Weinstein S, 382 Zalzstein E, 496 Steinbrede H, 373 Tsang LWW, 912 Weir SJ, 517, 798 Zariffa N, 129, 649 Stern R, 178 Tsujino D, 1025 Wei S, 625 Zhang Q, 625 Stern RH, 753 Tsunoda SM, 1137 Wekstein DR, 236 Zhou D, 625 Stowe CD, 1089 Tsuruta K, 40, 540 Welage LS, 708 Zhou H, 593 Strenkoski-Nix LC, 1063 Tsutsumi K, 68 Wells TG, 402, 994 Ziering R, 382 Sugimoto K, 442 Tullock W, 337 Wermeling DP, 236 Zimmermann T, 138 Subject Index, Volume 38 (1998) An “A” preceding a page number indicates an abstract. ABT-761 Chinese patients with type 2 diabetes mellitus movement and psychomotor function follow effects of ABT-761, a novel 5-lipoxygenase inhib- and mixed dislipidemia, 912 the same time course?, 337 itor, on the pharmacokinetics of a single dose Adverse Effects single-dose pharmacokinetics and pharmacody- of ethinyl estradiol and levonorgestrel in gender differences in adverse drug reactions, namics of alprazolam in elderly and young healthy female volunteers, 642 1003 subjects, 14 Acarbose paradoxical hypotension and bradycardia after Alzheimer’s disease impairment of absorption of digoxin by acarbose, ‘ntravenous arginine vasopressin, 283 application of population pharmacokinetics to 654 Age. See also Geriatrics; Pediatrics the phase II development of an anti- Alzhei- Acetaminophen influence of age on the safety, tolerability, and mer’s disease compound, S12024, 315 coadministration of acetaminophen and troglita- pharmacokinetics of the novel HMG-CoA re- pharmacokinetics, pharmacodynamics, and zone: pharmacokinetics and safety, 818 ductase inhibitor cerivastatin in healthy male safety of metrifonate in patients with Alzhei- mer’s disease, 236 Acetazolamide volunteers, 715 Amitriptyline pharmacokinetics of acetazolamide in healthy Albuterol multiple-dose pharmacokinetics and pharmaco- volunteers after short- and long-term exposure pharmacokinetic and pharmacodynamic charac- dynamics of OROS and immediate-release am- to high altitude, 533 teristics and safety of inhaled albuterol enan- itriptyline hydrochloride formulations, 60 Acipimox tiomers in healthy volunteers, 1096 Amphotericin B short-term efficacy and tolerability of combina- Alprazolam AmBisome (liposomal amphotericin B): a com- tion therapy with lovastatin and acipimox in do alprazolam-induced changes in saccadic eye parative review, 583 Analgesia metanide in critically ill pediatric patients, effect of cimetidine on the formation of sulfame- analgesic dose-response relationship of ibupro- 994 thoxazole hydroxylamine in patients with hu- fen 50, 100, 200, and 400 mg after surgical randomized, placebo-controlled study of loop di- man immunodeficiency virus, 463 removal of third molars: a single-dose, ran- uretics in patients with essential hypertension: influence of cimetidine on the disposition kinet- domized, placebo-controlled, and double- the Bumetanide and Furosemide on Lipid Pro- ics of the antidepressant venlafaxine, 467 blind study of 304 patients, 447 file (BUFUL) clinical study report, 630 Ciprofloxacin analgesic efficacy and safety of (R)-ketoprofen in pharmacodynamic interactions of ciprofloxacin, postoperative dental pain, 11S piperacillin, and piperacillin/tazobactam in comparative efficacy and safety of controlled- Calcipotriene healthy volunteers, 1063 release morphine suppositories and tablets in evadlauya tiinn gp attiheen tss awfeittyh posfo rciaalsciis:p otar ipearnael le3l0 grgo uppe,r Cisplatin cancer pain, 74 population pharmacokinetics and pharmacody- vehicle-controlled study, 368 double-blind, single-dose comparison of bromfe- Calcium namics of cisplatin in patients with cancer: nac sodium, tramadol, and placebo after oral sodium-calcium ion membrane exchanger: phys- analysis with the NONMEM program, 1025 surgery, 455 iologic significance and pharmacologic impli- Clarithromycin onset and duration of analgesia for low-dose ke- cations, 393 comparison of azithromycin and clarithromycin toprofen in the treatment of postoperative den- Calcium-Channel Blockers in their interactions with rifabutin in healthy tal pain, 1155 relevance of T-type calcium antagonists: a profile volunteers, 830 tramadol hydrochloride: analgesic efficacy com- of mibefradil, 659 Clinical Pharmacology pared with codeine, aspirin with codeine, and use of angiotensin-converting enzyme inhibitors Evening Reflections, 575 placebo after dental extraction, 554 as monotherapy and in combination with di- maturation of clinical pharmacology: recogniz- Aneurysms uretics and calcium-channel blockers, 477 ing the contributions of Dr. Louis Lasagna, 572 matrix metalloproteinases and abdominal aortic Cancer presentation of the Louis Lasagna Chair of Phar- Anganieoutreynssmisn:- Coan pvoetretnitnigal Etnhezryampeeu tIinch itbairtgoert,s 1077 comrpelaeraastei vmeo rpehffiincea cys upapnods itsoafreiteys oafn dc otnatbrloeltlse di-n Tmuafctosl oUgnyi verasnidt y SEcxhpoeorli meonf tMaeld iciTnhee,r ap5e7u0t ics, use of angiotensin-converting enzyme inhibitors cancer pain, 74 regulating angiogenesis: a new therapeutic strat- as monotherapy and in combination with di- pharmacokinetics of mitomycin C in pelvic stop- egy, 898 uretics and calcium-channel blockers, 477 flow infusion and hypoxic pelvic perfusion teaching clinical pharmacology and therapeu- Arginine Vasopressin with and without hemofiltration: a pilot study tics: selective for fourth-year medical students, paradoxical hypotension and bradycardia after of patients with recurrent unresectable rectal 670 intravenous arginine vasopressin, 283 cancer, 936 Clinical Trials ART-123 population pharmacokinetics and pharmacody- brompheniramine, loratadine, and placebo in al- novel recombinant soluble human _ thrombo- namics of cisplatin in patients with cancer: lergic rhinitis: a placebo-controlled compara- modulin, ART-123, activates the protein C analysis with the NONMEM program, 1025 tive clinical trial, 382 pathway in healthy male volunteers, 540 Cardiovascular System comparative efficacy and safety of controlled- phanarnmta coskoilnubeltei csh uamnadn satfehtryo mobf oma ondouvelli nr,e coAmRbTi-- chelation therapy in cardiovascular disease: eth- release morphine suppositories and tablets in ylenediaminetetraacetic acid, deferoxamine, cancer pain, 74 123, in healthy male volunteers, 40 and dexrazoxane, 101 cough-challenge trial with a new angiotensin- Aspirin droperido! elimination after cardiopulmonary converting enzyme inhibitor, imidapril, 442 trapmaardeodl wihtyhd rococdhelionrei,d e:a spainrailn gewsiitch ecfofdieciancye , coamn-d bypass surgery, 160 independence and statistical inference in clini- efficacy of intravenous granisetron in suppress- cal trial designs: a tutorial review, 408 placebo after dental extraction, 554 ing the bradycardia and hypotension associ- laboratory values and vital signs in male smokers Asthma ated with a rabbit model of the Bezold-Jarisch and non-smokers in phase I trails: a retrospec- infdliaatmomra tainotna,g oniinsftlsa mimna taosrtyh mam,e di5a7t7o rs, and me- impreofrltexa,n c1e7 2 of arterial compliance ion cardiovas- phatisvee Ic odmopuabrlies-oblni,n d,1 14p4l acebo-controlled, single Atorvastatin cular drug therapy, 202 rising dose study to determine the safety, tol- atorvastatin does not produce a clinically signif- innovative drug treatments for viral and autoim- erability, and pharmacokinetics of oral YM934 Acozmiincaptadahnirrtn ioesm,eoyf fnce7 ic5nt3o f oan zitthher opmhyacrimna caonkdi nectliacrsi thorfo mtyecrifen- iinnntmporuuvalnavmeteo invnomeauy sro ypc aharanrdrdeim stuaioscrscoa,ill t oa2gtp9iir5oco n p,a afp7ep6nr5o onaec hefsor ttor ecaatrmdeinot- plagimcnel elibhlmoieet-apuclisotr nhitydfr eoor ml aliwlenhed ,op mvaot liuednnritteasetn e drtowshi,met irhz4a e5p dyt ypies us2nt sududicyac beestse-os f in their interactions with rifabutin in healthy of tachycardia in infants and children: phar- volunteers, 830 macokinetics and clinical response, 496 ranfudlo, mi63z6e d, double-blind, placebo-controlled paradoxical hypotension and bradycardia after study of the safety and efficacy of vitamin B Baclofen phairntmraacvoeknionuest icarsg inoif nei ntvraasvoepnroeusss ina,n d 28o3r al losar- complex in the treatment of nocturnal leg inhibition of capsaicin-induced cough by the tan in patients with heart failure, 525 cramps in elderly patients with hypertension, gamma-aminobutyric acid agonist baclofen, pharmacokinetics of intravenous testosterone in 1151 364 elderly men with coronary artery disease, 792 randomized, placebo-controlled study of loop di- Benzodiazepines pharmacokinetics of torsemide in patients with uretics in patients with essential hypertension: problems and opportunities in regulation of ben- decompensated and compensated congestive the Bumetanide and Furosemide on Lipid Pro- zodiazepines, 773 heart failure, 708 file (BUFUL) clinical study report, 630 Bezold-Jarisch Reflex regulating angiogenesis: a new therapeutic strat- R-Ketoprofen in Clinical Trials, 1S efficacy of intravenous granisetron in suppress- egy, 898 serotonin uptake-enhancing drug tianeptine sup- ing the bradycardia and hypotension associ- sodium ion/hydrogen ion exchange inhibition: a presses asthmatic symptoms in children: a ated with a rabbit model of the Bezold-Jarisch new pharmacologic approach to myocardial double-blind, crossover, placebo-controlled reflex, 172 ischemia and reperfusion injury, 887 study, 918 BMS-188494 vasoreactivity in pre- and postmenopausal wom- short-term efficacy and tolerability of combina- clinical pharmacokinetics and pharmacodynam- en: evaluation by pharmacodynamic model- tion therapy with lovastatin and acipimox in ics of a new squalene synthase inhibitor, BMS- ing, 151 Chinese patients with type 2 diabetes mellitus 188494, in healthy volunteers, 1116 Cerivastatin and mixed dislipidemia, 912 Bromfenac influence of age on the safety, tolerability, and urine drug screening results from volunteers in double-blind, single-dose comparison of bromfe- pharmacokinetics of the nowel HMG-CoA re- phase I clinical pharmacology studies: are we nac sodium, tramadol, and placebo after oral ductase inhibitor cerivastatin in healthy male being misled?, 413 surgery, 455 volunteers, 715 Codeine metabolic disposition of 14C-bromfenac in Chlorzoxazone tramadol hydrochloride: analgesic efficacy com- healthy male volunteers, 744 use of chlorzoxazone as an in vivo probe of cy- pared with codeine, aspirin with codeine, and Brompheniramine tochrome P450 2E1: choice of dose and phe- placebo after dental extraction, 554 brompheniramine, loratadine, and placebo in al- notypic trait measure, 82 Coumarins lergic rhinitis: a placebo-controlled compara- Cilostazol lack of interaction between tramadol and couma- tive clinical trial, 382 pharmacokinetics of multiple-dose cilostazol in rins, 966 Bumetanide middle-age and elderly mem and women, 144 Cyclosporine pharmacokinetics and pharmacodynamics of bu- Cimetidine comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Chinese patients with type 2 diabetes mellitus levofloxacin and cyclosporine, 90 Sang-35 formulation and Neorol, 807 and mixed dislipidemia, 912 levonorgestrel and ABT-761, 642 effect of grapefruit juice on the pharmacokinetics Didanosine modafinil and dextroamphetamine, 971 of microemulsion cyclosporine and its metab- effect of high-dose oral ganciclovir on di- norethindrone and rifabutin and rifampicin, olite in healthy volunteers: does the formula- danosine disposition in human immunodefi- 1042 tion difference matter?, 959 ciency virus-positive patients, 1057 ondansetron and thiopental, 825 levofloxacin does not alter cyclosporine disposi- Digoxin pentoxifylline potentiates in vitro lymphocyte tion, 90 effect of troglitazone on steady-state pharmaco- suppression by glucocorticoids and immuno- CYP1A2 kinetics of digoxin, 178 suppressive drugs, 561 absence of effect of terbinafine on the activity of impairment of absorption of digoxin by acarbose, piperacillin and ciprofloxacin and piperacillin/ CYP1A2, NAT-2, and xanthine oxidase, 424 654 tazobactam, 1063 Cysteine Diphenhydramine piperacillin/tazobactam and piperacillin and pharmacokinetics of 2-oxothiazolidine-4-carbox- pharmacokinetics and pharmacodynamics of di- ciprofloxacin, 1063 ylate, a cysteine prodrug, and cysteine, 945 phenhydramine 25 mg in young and elderly rifabutin and azithromycin, 830 Cystic Fibrosis volunteers, 603 rifabutin and clarithromycin, 830 pharmacokinetics of famotidine in patients with Dislipidemia rifabutin and rifampicin and ethinyl estradiol, cystic fibrosis, 1017 short-term efficacy and tolerability of combina- 1042 Cytochrome P450 tion therapy with lovastatin and acipimox in rifabutin and rifampicin and norethindrone, preliminary evaluation of progestins as inducers Chinese patients with type 2 diabetes mellitus 1042 of cytochrome P450 3A4 activity in postmeno- and mixed dislipidemia, 912 rifampicin and rifabutin and ethinyl! estradiol, pausal women, 1137 Diuretics 1042 protease inhibitors as inhibitors of human cyto- use of angiotensin-converting enzyme inhibitors rifampicin and rifabutin and norethindrone, chromes P450: high risk associated with as monotherapy and in combination with di- 1042 ritonavir, 106 uretics and calcium-channel blockers, 477 single-dose pharmacokinetics of modafinil and use of chlorzoxazone as an in vivo probe of cy- Dolasetron Mesylate methylphenidate given alone or in combina- tochrome P450 2E1: choice of dose and phe- pharmacokinetics of oral and intravenous dolas- tion in healthy male volunteers, 276 notypic trait measure, 82 etron mesylate in patients with renal impair- sulfamethoxazole and cimetidine, 463 ment, 798 terazosin and finasteride, 1072 Doxazosin terfenadine and atorvastatin, 753 Deferoxamine pharmacokinetic interaction between finasteride thiopental and ondansetron, 825 chelation therapy in cardiovascular disease: eth- and terazosin, but not finasteride and doxazo- tiagabine and erythromycin, 1051 ylenediaminetetraacetic acid, deferoxamine, sin, 1072 tramadol and coumarins, 966 and dexrazoxane, 101 Droperidol troglitazone and acetaminophen, 819 Dementia droperidol elimination after cardiopulmonary troglitazone and digoxin, 178 KA 672-HCI, a neuronal activator against demen- bypass surgery, 160 venlafaxine and cimetidine, 467 tia: tolerability, safety, and preliminary phar- Drug Delivery warfarin and eprosartan, 649 macokinetics after single and multiple oral fentanyl delivery from an electrotransport sys- Drug Metabolism doses in healthy male and female volunteers, tem: delivery is a function of total current, not absence of effect of terbinafine on the activity of 373 duration of current, 951 CYP1A2, NAT-2, and xanthine oxidase, 424 Demographics Drug Development effects of extensive and poor gastrointestinal me- pharmacodynamics and pharmacokinetics of a application of population pharmacokinetics to tabolism on the pharmacodynamics of prava- single oral dose of nitrazepam in healthy vol- the phase II development of an anti- Alzhei- statin, 331 unteers: an interethnic comparative study be- mer’s disease compound, $12024, 315 metabolic disposition of 14C-bromfenac in tween Japanese and European volunteers, performance of human mass balance studies healthy male volunteers, 744 1129 with stable isotope-labeled drug and continu- preliminary evaluation of progestins as inducers Dental Pain ous flow-isotope ratio mass spectrometry: a of cytochrome P450 3A4 activity in postmeno- analgesic dose-response relationship of ibupro- progress report, 309 pausal women, 1137 fen 50, 100, 200, and 400 mg after surgical stable isotope techniques in early drug develop- protease inhibitors as inhibitors of human cyto- removal of third molars: a single-dose, ran- ment: an economic evaluation, 213 chromes P450: high risk associated with domized, placebo-controlled, and double- Drug Interactions ritonavir, 106 blind study of 304 patients, 447 ABT-761 and ethinyl! estradiol, 642 use of chlorzoxazone as an in vivo probe of cy- analgesic efficacy and safety of (R)-ketoprofen in ABT-761 and levonorgestrel, 642 tochrome P450 2E1: choice of dose and phe- postoperative dental pain, 11S acarbose and digoxin, 654 notypic trait measure, 82 double-blind, single-dose comparison of bromfe- acetaminophen and troglitazone, 819 nac sodium, tramadol, and placebo after oral atorvastatin and terfenadine, 753 Editorials surgery, 455 azithromycin and rifabutin, 830 Editor’s Note, 569 onset and duration of analgesia for low-dose ke- cimetidine and sulfamethoxazole, 463 A New Look, 1 toprofen in the treatment of postoperative den- cimetidine and venlafaxine, 467 Products Approved for Marketing During 1997, tal pain, 1155 ciprofloxacin and piperacillin and piperacillin/ 199 tramadol hydrochloride: analgesic efficacy com- tazobactam, 1063 R-Ketoprofen in Clinical Trials, 1S pared with codeine, aspirin with codeine, and clarithromycin and rifabutin, 830 Elderly Patients. See Geriatrics placebo after dental extraction, 554 coumarins and tramadol, 966 Eprosartan Dexrazoxane cyclosporine and levofloxacin, 90 dose proportionality study of eprosartan in chelation therapy in cardiovascular disease: eth- dextroamphetamine and modafinil, 971 healthy male volunteers, 34 ylenediaminetetraacetic acid, deferoxamine, didanosine and ganciclovir, 1051 effects of eprosartan, an angiotensin II AT1 re- and dexrazoxane, 101 digoxin and acarbose, 654 ceptor antagonist, on uric acid excretion in Dextroamphetamine digoxin and troglitazone, 178 patients with mild to moderate essential hy- comparison of single-dose pharmacokinetics and doxazosin and finasteride, 1072 pertension, 437 tolerability of modafinil and dextroamphet- effect of grapefruit juice on the pharmacokinetics eprosartan does not affect the pharmacodynam- amine administered alone or in combination of microemulsion cyclosporine and its metab- ics of warfarin, 649 in healthy male volunteers, 971 olite in healthy volunteers: does the formula- pharmacokinetics and protein binding of epro- Diabetes Mellitus tion difference matter?, 959 sartan in healthy volunteers and in patients lipid and lipoprotein responses to oral combined eprosartan and warfarin, 649 with varying degrees of renal impairment, 129 hormone replacement therapy in normoli- erythromycin and felbamate, 184 Eptastigmine pemia obese women with controlled type 2 erythromycin and tiagabine, 1051 maximum tolerated dose and pharmacodynam- diabetes mellitus, 1107 ethinyl estradiol and ABT-761, 642 ics of eptastigmine in elderly healthy volun- placebo-controlled, randomized study of ethinyl estradiol and rifabutin and rifampicin, teers, 610 glimepiride in patients with type 2 diabetes 1042 Erythromycin mellitus for whom diet therapy is unsuccess- felbamate and erythromycin, 184 effect of multiple doses of rifampin on the (14C ful, 636 finasteride and doxazosin, 1072 N-methyl) erythromycin breath test in healthy short-term efficacy and tolerability of combina- finasteride and terazosin, 1072 male volunteers, 492 tion therapy with lovastatin and acipimox in ganciclovir and didanosine, 1051 evaluation of the potential interaction between 1169 felbamate and erythromycin in patients with ceiving long-term methadone maintenance, phase I/II evaluation of oral L-2-oxothiazolidine- epilepsy, 184 931 4-carboxylic acid in asymptomatic patients in- lack of pharmacokinetic interaction between Gender fected with human immunodeficiency virus, tiagabine and erythromycin, 1051 effects of gender on adrenergic receptor respon- 357 Ethinyl estradiol siveness, 618 steady-state relative bioavailability of three oral effects of ABT-761, a novel 5-lipoxygenase inhib- gender differences in adverse drug reactions, ganciclovir dosage regimens delivering 6,000 itor, on the pharmacokinetics of a single dose 1003 mg/day in patients with human immunodefi- of ethinyl estradiol and levonorgestrel in Geriatrics ciency virus, 1021 healthy female volunteers, 642 maximum tolerated dose and pharmacodynam- Hydrogen effects of rifabutin and rifampicin on the phar- ics of eptastigmine in elderly healthy volun- sodium ion/hydrogen ion exchange inhibition: a macokinetics of ethinyl! estradiol and noreth- teers, 610 new pharmacologic approach to myocardial indrone, 1042 pharmacokinetics and pharmacodynamics of di- ischemia and reperfusion injury, 887 Ethnicity phenhydramine 25 mg in young and elderly Hypertension pharmacodynamics and pharmacokinetics of a volunteers, 603 effects of eprosartan, an angiotensin II AT1 re- single oral dose of nitrazepam in healthy vol- pharmacokinetics of intravenous testosterone in ceptor antagonist, on uric acid excretion in unteers: an interethnic comparative study be- elderly men with coronary artery disease, 792 patients with mild to moderate essential hy- tween Japanese and European volunteers, pharmacokinetics of multiple-dose cilostazol in pertension, 437 1129 middle-age and elderly men and women, 144 fenoldopam: a new dopamine agonist for the Ethylenediaminetetraacetic acid randomized, double-blind, placebo-controlled treatment of hypertensive urgencies and emer- chelation therapy in cardiovascular disease: eth- study of the safety and efficacy of vitamin B gencies, 2 ylenediaminetetraacetic acid, deferoxamine, complex in the treatment of nocturnal leg pharmacokinetics and pharmacodynamics of and dexrazoxane, 101 cramps in elderly patients with hypertension, zolmitriptan in patients with mild to moderate Extracorporeal Membrane Oxygenation 1151 hypertension: a double-blind, placebo-con- pharmacokinetics and pharmacodynamics of ra- single-dose pharmacokinetics and pharmacody- trolled study, 685 nitidine in neonates treated with extracorpo- namics of alprazolam in elderly and young randomized, double-blind, placebo-controlled real membrane oxygenation, 402 subjects, 14 study of the safety and efficacy of vitamin B Glimepiride complex in the treatment of nocturnal leg Famotidine placebo-controlled, randomized study of cramps in elderly patients with hypertension, effect of increasing gastric pH with famotidine glimepiride in petients with type 2 diabetes 1151 on the absorption and oral pharmacokinetics mellitus for whom diet therapy is unsuccess- Hypokalemia of the inotropic agent vesnarinone, 429 ful, 636 effect of varying molar ratios of potassium-mag- pharmacokinetics of famotidine in patients with Glucocorticoids nesium citrate on thiazide-induced hypokale- cystic fibrosis, 1017 pentoxifylline potentiates in vitro lymphocyte mia and magnesium loss, 1035 Felbamate suppression by glucocorticoids and immuno- Hypotension evaluation of the potential interaction between suppressive drugs, 561 efficacy of intravenous granisetron in suppress- felbamate and erythromycin in patients with Granisetron ing the bradycardia and hypotension associ- epilepsy, 184 efficacy of intravenous granisetron in suppress- ated with a rabbit model of the Bezold-Jarisch Fenoldopam ing the bradycardia and hypotension associ- reflex, 172 fenoldopam: a new dopamine agonist for the ated with a rabbit model of the Bezold-Jarisch paradoxical hypotension and bradycardia after treatment of hypertensive urgencies and emer- reflex, 172 intravenous arginine vasopressin, 283 gencies, 2 Grapefruit Juice Fentanyl effect of grapefrait juice on the pharmacokinetics fentanyl delivery from an electrotransport sys- of microemulsion cyclosporine and its metab- Ibuprofen tem: delivery is a function of total current, not olite in healthy volunteers: does the formula- analgesic dose-response relationship of ibupro- duration of current, 951 tion difference matter?, 959 fen 50, 100, 200, and 400 mg after surgical Finasteride removal of third molars: a single-dose, ran- pharmacokinetic interaction between finasteride Hemodynamics domized, placebo-controlled, and double- and terazosin, but not finasteride and doxazo- short-term effects of nicardipine and propranolol blind study of 304 patients, 447 sin, 1072 on ocular and systemic hemodynamics in Imidapril Fluconazole healthy Japanese subjects, 68 cough-challenge trial with a new angiotensin- accumulation of fluconazole in scalp hair, 138 Hepatic Function converting enzyme inhibitor, imidapril, 442 Flurbiprofen effect of hepatic impairment on the pharmacoki- Immunosuppressive Drugs clinical endoscopic evaluation of gastroduode- netics of zolmitriptan, 694 pentoxifylline potentiates in vitro lymphocyte nal tolerance to (R)-ketoprofen, (R)-flurbipro- pharmacokinetics and pharmacodynamics of suppression by glucocorticoids and immuno- fen, racemic ketoprofen and paracetamol; a irbesartan in patients with hepatic cirrhosis, suppressive drugs, 561 randomized, single-blind, placebo-controlled 347 Inflammation trial, 19S pharmacokinetics of rifapentine in patients with inflammation, inflammatory mediators, and me- Furosemide varying degrees of hepatic dysfunction, 517 diator antagonists in asthma, 577 randomized, placebo-controlled study ofl oop di- High Altitude Irbesartan uretics in patients with essential hypertension: pharmacokinetics of acetazolamide in healthy lack of effect of food on the oral bioavailability of the Bumetanide and Furosemide on Lipid Pro- volunteers after short- and long-term exposure irbesartan in healthy male volunteers, 433 file (BUFUL) clinical study report, 630 to high altitude, 533 oral bioavailability and disposition characteris- Hormone Replacement Therapy tics of irbesartan, an angiotensin antagonist, in Ganciclovir lipid and lipoprotein responses to oral combined healthy volunteers, 702 absolute bioavailability and dose proportionality hormone replacement therapy in normoli- pharmacokinetics and pharmacodynamics of of oral ganciclovir after ascending multiple pemia obese women with controlled type 2 irbesartan in healthy subjects, 246 doses in human immunodeficiency virus-pos- diabetes mellitus, 1107 pharmacokinetics and pharmacodynamics of itive patients, 1122 Human Immunodeficiency Virus irbesartan in patients with hepatic cirrhosis effect of high-dose oral ganciclovir on di- absolute bioavailability and dose proportionality irbesartan, 347 danosine disposition in human immunodefi- of oral ganciclovir after ascending multiple Itraconazole ciency virus-positive patients, 1057 doses in human immunodeficiency virus-pos- pharmacokinetic study of intravenous itracon- steady-state relative bioavailability of three oral itive patients, 1122 azole followed by oral administration of itra- ganciclovir dosage regimens delivering 6,000 effect of cimetidine on the formation of sulfame- conazole capsules in patients with advanced mg/day in patients with human immunodefi- thoxazole hydroxylamine in patients with hu- human immunodeficiency virus infection, 593 ciency virus, 1021 man immunodeficiency virus, 463 Gastrointestinal System effect of high-dose oral ganciclovir on di- effects of extensive and poor gastrointestinal me- danosine disposition in human immunodefi- KA 672-HCl tabolism on the pharmacodynamics of prava- ciency virus-positive patients, 1057 KA 672-HCIl, a neuronal activator against demen- statin, 331 pharmacokinetic study of intravenous itracon- tia: tolerability, safety, and preliminary phar- effects of low-dose morphine on gastric empty- azole followed by oral administration of itra- macokinetics after single and multiple oral ing in healthy volunteers, 1017 conazole capsules in patients with advanced doses in healthy male and female volunteers, gut motility and transit changes in patients re- human immunodeficiency virus infection, 593 373 Ketoprofen release morphine suppositories and tablets in pharmacokinetics and pharmacodynamics of fa- analgesic efficacy and safety of (R)-ketoprofen in cancer pain, 74 motidine in infants, 1089 postoperative dental pain, 11S effects of low-dose morphine on gastric empty- pharmacokinetics and pharmacodynamics of ra- onset and duration of analgesia for low-dose ke- ing in healthy volunteers, 1017 nitidine in neonates treated with extracorpo- toprofen in the treatment of postoperative den- Mycophenolic acid real membrane oxygenation, 402 tal pain, 1155 pharmacokinetics of mycophenolic acid in renal pharmacokinetics of metoclopramide in neo- R-Ketoprofen in Clinical Trials, 1S transplant patients with delayed graft func- nates, 122 stereoselective pharmacokinetics and inversion tion, 276 serotonin uptake-enhancing drug tianeptine sup- of (R)-ketoprofen in healthy volunteers, 3S presses asthmatic symptoms in children: a Ketorolac Naproxen double-blind, crossover, placebo-controlled preclinical enantioselective pharmacology of single- and multiple-dose pharmacokinetic com- study, 918 (R)- and (S)-ketorolac, 24S parison of a sustained-release tablet and con- steady-state pharmacokinetics of isotretinoin ventional tablets of naproxen in healthy vol- and its 4-oxo metabolite: implications for fetal Letrozole unteers, 625 safety, 926 plasma protein binding of letrozole, a new non- NAT-2 Pentoxifylline steroidal aromatase enzyme inhibitor, 727 absence of effect of terbinafine on the activity of pentoxifylline potentiates in vitro lymphocyte Levofloxacin CYP1A2, NAT-2, and xanthine oxidase, 424 suppression by glucocorticoids and immuno- levofloxacin does not alter cyclosporine disposi- Nicardipine suppressive drugs, 561 tion, 90 short-term effects of nicardipine and propranolol Pharmacodynamics Levonorgestrel on ocular and systemic hemodynamics in albuterol, 1096 effects of ABT-761, a novel 5-lipoxygenase inhib- healthy Japanese subjects, 68 alprazolam, 14 itor, on the pharmacokinetics of a single dose Nicotine. See also Smoking amitriptyline, 60 of ethinyl estradiol and levonorgestrel in application of serum nicotine and plasma cotin- baclofen, 364 healthy female volunteers, 642 ine concentrations to assessment of nicotine BMS-188494, 1116 Loratadine replacement in light, moderate, and heavy bumetanide, 994 brompheniramine, loratadine, and placebo in al- smokers undergoing transdermal therapy, 502 cisplatin, 1025 lergic rhinitis: a placebo-controlled compara- application of urine nicotine and plasma cotin- diphenhydramine, 603 tive clinical trial, 382 ine concentrations to assessment of nicotine effects of gender on adrenergic receptor respon- Losartan replacement in light, moderate, and heavy siveness, 618 pharmacokinetics of intravenous and oral losar- smokers undergoing transdermal therapy, 510 eptastigmine, 610 tan in patients with heart failure, 525 plasma nitric oxide before and after smoking ces- famotidine, 1089 Lovastatin sation with nicotine nasal spray, 22 hormone replacement therapy, 1107 short-term efficacy and tolerability of combina- Nitrazepam irbesartan, 246, 347 tion therapy with lovastatin and acipimox in pharmacodynamics and pharmacokinetics of a metrifonate, 236 Chinese patients with type 2 diabetes mellitus single oral dose of nitrazepam in healthy vol- morphine, 1017 and mixed dislipidemia, 912 unteers: an interethnic comparative study be- nicardipine, 68 Lymphocytes tween Japanese and European volunteers, nicotine, 502, 510 pentoxifylline potentiates in vitro lymphocyte 1129 nitrazepam, 1129 suppression by glucocorticoids and immuno- Nitric Oxide L-2-oxothiazolidine-4-carboxylic acid, 357 suppressive drugs, 561 plasma nitric oxide before and after smoking ces- pravastatin, 331 sation with nicotine nasal spray, 22 propranolol, 68 Magnesium Norethindrone pyridostigmine bromide, 227 effect of varying molar ratios of potassium-mag- effects of rifabutin and rifampicin on the phar- ranitidine, 402 nesium citrate on thiazide-induced hypokale- macokinetics of ethinyl estradiol and noreth- terazosin, 545 mia and magnesium loss, 1035 indrone, 1042 vasoreactivity in pre- and postmenopausal wom- Metalloproteinases Nuclear Factor KappaB en: evaluation by pharmacodynamic model- matrix metalloproteinases and abdominal aortic nuclear factor kappaB: important transcription ing, 151 aneurysms: a potential therapeutic target, 1077 factor and therapeutic target, 981 venlafaxine, 256 Methadone Pharmacoeconomics gut motility and transit changes in patients re- Obesity pharmacoeconomic model to aid in the alloca- ceiving long-term methadone maintenance, lipid and lipoprotein responses to oral combined tion of ambulatory clinical pharmacy services, 931 hormone replacement therapy in normoli- 783 Methylphenidate pemia obese women with controlled type 2 Pharmacoepidemiology single-dose pharmacokinetics of modafinil and diabetes mellitus, 1107 gender differences in adverse drug reactions, methylphenidate given alone or in combina- Ondansetron 1003 tion in healthy male volunteers, 276 influence of ondansetron on thiopental hypnotic Pharmacokinetics Metoclopramide requirements, 825 acetazolamide, 533 pharmacokinetics of metoclopramide in neo- OROS albuterol, 1096 nates, 122 multiple-dose pharmacokinetics and pharmaco- alprazolam, 14 Metrifonate dynamics of OROS and immediate-release am- amitriptyline, 60 pharmacokinetics, pharmacodynamics, and itriptyline hydrochloride formulations, 60 ART-123, 40, 540 safety of metrifonate in patients with Alzhei- 2-Oxothiazolidine-4-Carboxylate assessment of drug accumulation in the evalua- mer’s disease, 236 pharmacokinetics of 2-oxothiazolidine-4-carbox- tion of pharmacokinetic data, 685 Mibefradil ylate, a cysteine prodrug, and cysteine, 945 balanced designs in longitudinal population relevance of T-type calcium antagonists: a profile phase I/II evaluation of oral L-2-oxothiazolidine- pharmacokinetic studies, 417 of mibefradil, 659 4-carboxylic acid in asymptomatic patients in- BMS-188494, 1116 Mitomycin C fected with human immunodeficiency virus, bumetanide, 994 pharmacokinetics of mitomycin C in pelvic stop- 357 cerivastatin, 715 flow infusion and hypoxic pelvic perfusion cilostazol, 144 with and without hemofiltration: a pilot study Paracetamol cisplatin, 1025 of patients with recurrent unresectable rectal clinical endoscopic evaluation of gastroduode- coadministration of acetaminophen and troglita- cancer, 936 nal tolerance to (R)-ketoprofen, (R)-flurbipro- zone: pharmacokinetics and safety, 818 Modafinil fen, racemic ketoprofen and paracetamol; a cyclosporine, 807 comparison of single-dose pharmacokinetics and randomized, single-blind, placebo-controlled cysteine, 945 tolerability of modafinil and dextroamphet- trial, 19S development of a limited sampling approach in amine administered alone or in combination Pediatrics pharmacokinetic studies: experience with the in healthy male volunteers, 971 intravenous and oral propafenone for treatment antiepilepsy drug tiagabine, 324 single-dose pharmacokinetics of modafinil and of tachycardia in infants and children: phar- dextroamphetamine, 971 methylphenidate given alone or in combina- macokinetics and clinical response, 496 diphenhydramine, 603 tion in healthy male volunteers, 276 pharmacokinetics and pharmacodynamics of bu- dolasetron mesylate, 798 Morphine metanide in critically ill pediatric patients, dose proportionality study of eprosartan in comparative efficacy and safety of controlled- 994 healthy male volunteers, 34 droperidol, 160 short-term effects of nicardipine and propranolol doses in healthy male and female volunteers, effect of grapefruit juice on the pharmacokinetics on ocular and systemic hemodynamics in 373 of microemulsion cyclosporine and its metab- healthy Japanese subjects, 68 pharmacokinetic and pharmacodynamic charac- EPRfADecS es EE olite in healthy volunteers: does the formula- Protein C Pathway teristics and safety of inhaled albuterol enan- tion difference matter?, 959 novel recombinant soluble human _ thrombo- tiomers in healthy volunteers, 1096 effect of multiple doses of rifampin on the (14C modulin, ART-123, activates the protein C pharmacokinetics, pharmacodynamics, and N-methyl) erythromycin breath test in healthy pathway in healthy male volunteers, 540 safety of metrifonate in patients with Alzhei- male volunteers, 492 Psoriasis mer’s disease, 236 eprosartan, 129 evaluating the safety of calcipotriene 30 g per pharmacokinetics and safety of a novel recombi- erythromycin, 1051 day in patients with psoriasis: a parallel group, nant soluble human thrombomodulin, ART- ethinyl estradiol, 1042 vehicle-controlled study, 368 123, in healthy male volunteers, 40 famotidine, 1089, 429, 1010 Psychopharmacology phase I double-blind, placebo-controlled, single fluconazole, 138 do alprazolam-induced changes in saccadic eye rising dose study to determine the safety, tol- ganciclovir, 1021, 1122 movement and psychomotor function follow erability, and pharmacokinetics of oral YM934 ignorability and parameter estimation in longitu- the same time course?, 337 in healthy male volunteers, 45 dinal pharmacokinetic studies, 221 Pyridostigmine Bromide randomized, double-blind, placebo-controlled irbesartan, 246, 347, 433, 702 population pharmacokinetics and pharmacody- study of the safety and efficacy of vitamin B isotretinoin, 926 namics of pyridostigmine bromide for prophy- complex in the treatment of nocturnal leg itroconazole, 593 laxis against nerve agents in humans, 227 cramps in elderly patients with hypertension, KA 672-HCl, 373 1151 ketoprofen, 3S Ranitidine Scopolamine letrozole, 727 pharmacokinetics and pharmacodynamics of pharmacokinetics and pharmacodynamics of ra- losartan, 517 scopolamine after subcutaneous administra- methadone, 931 nitidine in neonates treated with extracorpo- tion, 720 real membrane oxygenation, 402 methylphenidate, 276 Renal Function Seizures metoclopramide, 122 steady-state pharmacokinetics of zonisamide, effects of renal impairment in the pharmacoki- metrifonate, 236 and antiepileptic agent for treatment of refrac- netics of zalcitabine, 28 mitomycin C, 936 tory complex partial seizures, 166 modafinil, 276, 971 pharmacokinetics and protein binding of epro- Serotonin sartan in healthy volunteers and in patients mycophenolic acid, 268 serotonin uptake-enhancing drug tianeptine sup- with varying degrees of renal impairment, 129 naproxen, 625 pharmacokinetics of mycophenolic acid in renal presses asthmatic symptoms in children: a nelfinavir, 736 double-blind, crossover, placebo-controlled transplant patients with delayed graft func- nicotine nasal spray, 22 study, 918 tion, 276 nitrazepam, 1129 Smoking. See also Nicotine pharmacokinetics of oral and intravenous dolas- norethindrone, 1042 laboratory values and vital signs in male smokers 2-oxothiazolidine-4-carboxylate, 945 etron mesylate in patients with renal impair- and non-smokers in phase I trails: a retrospec- ment, 798 L-2-oxothiazolidine-4-carboxylic acid, 357 tive comparison, 1144 potassium-magnesium citrate, 1035 Rhinitis Sodium brompheniramine, loratadine, and placebo in al- propafenone, 496 sodium-calcium ion membrane exchanger: phys- lergic rhinitis: a placebo-controlled compara- pyridostigmine bromide, 227 iologic significance and pharmacologic impli- tive clinical trial, 382 ranitidine, 402 cations, 393 Rifabutin rifampin, 492 sodium ion/hydrogen ion exchange inhibition: a comparison of azithromycin and clarithromycin rifapentine, 517 new pharmacologic approach to myocardial in their interactions with rifabutin in healthy $s1c2o0p2o4l,a mi3n1e5, 721 effveoctlsu ntoefe rrsi,f ab8u3t0i n and rifampicin on the phar- Sulisfcahmeemtihao xaazndo ler eperfusion injury, 887 testosterone, 54, 792 effect of cimetidine on the formation of sulfame- tiagabine, 324, 1051 macokinetics of ethinyl estradiol and noreth- thoxazole hydroxylamine in patients with hu- indrone, 1042 torsemide, 708 man immunodeficiency virus, 463 Rifampicin troglitazone, 815 venlafaxine, 256, 467 effmecatcso kiofn ertiifcasb utionf eatnhdi nyrli feasmtpriacdiino l ona ndt hen orpehtahr-- Terazosin vesnarinone, 429 pharmacokinetic interaction between finasteride indrone, 1042 when are bioavailability studies required? A Ger- and terazosin, but not finasteride and doxazo- Rifapentine man proposal, 904 sin, 1072 YM934,4 5 phavarrmyaicnogk idneegtriecess ooff rhiefpaapteinct indey sfiunn cptatiioenn,t s 51w7i th Terbinafine zalcitabine, 28 absence of effect of terbinafine on the activity of Ritonavir zolmitriptan, 685, 694 CYP1A2, NAT-2, and xanthine oxidase, 424 zonisamide, 166 protease inhibitors as inhibitors of human cyto- Terfenadine chromes P450: high risk associated with Piperacillin atorvastatin does not produce a clinically signif- ritonavir, 106 pharmacodynamic interactions of ciprofloxacin, icant effect on the pharmacokinetics of terfe- piperacillin, and piperacillin/tazobactam in nadine, 753 healthy volunteers, 1063 $12024 Testosterone Piperacillin/Tazobactam application of population pharmacokinetics to bioequivalence assessment of a single 5 mg/day pharmacodynamic interactions of ciprofloxacin, the phase II development of an anti- Alzhei- testosterone transdermal system versus two piperacillin, and piperacillin/tazobactam in mer’s disease compound, $12024, 315 2.5 mg/day systems in hypogonadal men, 54 healthy volunteers, 1063 Safety pharmacokinetics of intravenous testosterone in Potassium-Magnesium Citrate analgesic efficacy and safety of (R)-ketoprofen in elderly men with coronary artery disease, 792 effect of varying molar ratios of potassium-mag- postoperative dental pain, 11S Thiazides nesium citrate on thiazide-induced hypokale- coadministration of acetaminophen and troglita- effect of varying molar ratios of potassium-mag- mia and magnesium loss, 1035 zone: pharmacokinetics and safety, 818 nesium citrate on thiazide-induced hypokale- Pravastatin comparative efficacy and safety of controlled- mia and magnesium loss, 1035 effects of extensive and poor gastrointestinal me- release morphine suppositories and tablets in Thiopental tabolism on the pharmacodynamics of prava- cancer pain, 74 influence of ondansetron on thiopental hypnotic statin, 331 evaluating the safety of calcipotriene 30 g per requirements, 825 Progestins day in patients with psoriasis: a parallel group, Tiagabine preliminary evaluation of progestins as inducers vehicle-controlled study, 368 development of a limited sampling approach in of cytochrome P450 3A4 activity in postmeno- influence of age on the safety, tolerability, and pharmacokinetic studies: experience with the pausal women, 1137 pharmacokinetics of the novel HMG-CoA re- antiepilepsy drug tiagabine, 324 Propafenone ductase inhibitor cerivastatin in healthy male lack of pharmacokinetic interaction between intravenous and oral propafenone for treatment volunteers, 715 tiagabine and erythromycin, 1051 of tachycardia in infants and children: phar- KA 672-HCI, a neuronal activator against demen- Tianeptine macokinetics and clinical response, 496 tia: tolerability, safety, and preliminary phar- serotonin uptake-enhancing drug tianeptine sup- Propranolol macokinetics after single and multiple oral presses asthmatic symptoms in children: a double-blind, crossover, placebo-controlled Tramadol Hydrochloride eprosartan does not affect the pharmacodynam- study, 918 tramadol hydrochloride: analgesic efficacy com- ics of warfarin, 649 Tolerability pared with codeine, aspirin with codeine, and influence of age on the safety, tolerability, and placebo after dental extraction, 554 pharmacokinetics of the novel HMG-CoA re- Troglitazone Xanthine Oxidase ductase inhibitor cerivastatin in healthy male effect of troglitazone on steady-state pharmaco- absence of effect of terbinafine on the activity of volunteers, 715 kinetics of digoxin, 178 CYP1A2, NAT-2, and xanthine oxidase, 424 KA 672-HCI, a neuronal activator against demen- effect of troglitazone on urinary excretion of 6B- tia: tolerability, safety, and preliminary phar- hydroxycortisol, 815 YM934 macokinetics after single and multiple oral phase I double-blind, placebo-controlled, single doses in healthy male and female volunteers, Uric Acid rising dose study to determine the safety, tol- 373 effects of eprosartan, an angiotensin II AT1 re- erability, and pharmacokinetics of oral YM934 phase I double-blind, placebo-controlled, single ceptor antagonist, on uric acid excretion in in healthy male volunteers, 45 rising dose study to determine the safety, tol- patients with mild to moderate essential hy- Young Adults erability, and pharmacokinetics of oral YM934 pertension, 437 pharmacokinetics and pharmacodynamics of di- in healthy male volunteers, 45 phenhydramine 25 mg in young and elderly short-term efficacy and tolerability of combina- Ctihoinn etshee rpaaptyi enwtist h wiltohv asttyaptei n2 dainadb etaecsi pmiemlolxi tuisn Vabesnollauftaex inbei oavailability and electroencephalo- sinvgolleu-ndtoeseer s,p h6a0r3m acokinetics and pharmacody- Tolaenrda nmciex ed dislipidemia, 912 grerlaepahsiec feofrfmecutlsa toifo ncso nvofe nvteinolnaafla xianned ienx theenadletdh-y snuabmjieccsts , of1 4 alprazolam in elderly and young clinical endoscopic evaluation of gastroduode- subjects, 256 nal tolerance to (R)-ketoprofen, (R)-flurbipro- influence of cimetidine on the disposition kinet- Zalcitabine fen, racemic ketoprofen and paracetamol; a ics of the antidepressant venlafaxine, 467 effects of renal impairment in the pharmacoki- randomized, single-blind, placebo-controlled Vesnarinone netics of zalcitabine, 28 trial, 19S effect of increasing gastric pH with famotidine Zolmitriptan Torsemide on the absorption and oral pharmacokinetics effect of hepatic impairment on the pharmacoki- pharmacokinetics of torsemide in patients with of the inotropic agent vesnarinone, 429 netics of zolmitriptan, 694 decompensated and compensated congestive Vitamin B Complex pharmacokinetics and pharmacodynamics of heart failure, 708 randomized, double-blind, placebo-controlled zolmitriptan in patients with mild to moderate Tramadol study of the safety and efficacy of vitamin B hypertension: a double-blind, placebo-con- double-blind, single-dose comparison of bromfe- complex in the treatment of nocturnal leg trolled study, 685 nac sodium, tramadol, and placebo after oral cramps in elderly patients with hypertension, Zonisamide surgery, 455 1151 steady-state pharmacokinetics of zonisamide, lack of interaction between tramadol and couma- and antiepileptic agent for treatment of refrac- rins, 966 Warfarin tory complex partial seizures, 166